GLP-1 Side Effects Compared: Semaglutide vs Tirzepatide
Both semaglutide and tirzepatide most commonly cause gastrointestinal side effects — nausea, diarrhea, vomiting, constipation. Rates are broadly similar; slow dose titration is the main strategy to reduce them. These effects are usually mild to moderate, worst during dose escalation, and improve as the body adapts; slow titration is the main evidence-based way to reduce them, and severe or persistent symptoms warrant clinical review.
- GI effects (nausea, diarrhea, vomiting, constipation) are the most common for both drugs.
- Side effects are usually worst during dose escalation and often ease over time.
- Both carry a boxed warning for thyroid C-cell tumors based on rodent studies.
- Slow titration is the primary evidence-based strategy to reduce GI effects.
The common side effects
Both semaglutide and tirzepatide share a side-effect profile dominated by the gastrointestinal tract: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These are the effects most people experience, and they are usually most intense during dose escalation before easing as the body adjusts.
Across the STEP and SURMOUNT trials, the majority of participants reported at least one GI effect, but most were mild to moderate and relatively few discontinued because of them.
Do they differ between the drugs?
Head-to-head, the side-effect profiles are broadly similar. Both drugs work through GLP-1 receptor activation, which drives the GI effects, and tirzepatide's additional GIP activity does not appear to dramatically change the tolerability picture for most people.
Some individuals tolerate one molecule better than the other, which is not fully predictable in advance. If side effects on one are intolerable, a clinician may consider switching, but there is no universal rule that one is gentler.
| Effect | Frequency | Usually worst when |
|---|---|---|
| Nausea | Very common | Dose escalation |
| Diarrhea | Common | Dose escalation |
| Constipation | Common | Ongoing |
| Vomiting | Common | Dose escalation |
The serious warnings
Both carry a boxed warning for thyroid C-cell tumors, based on rodent studies; they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both list a risk of pancreatitis, gallbladder problems, and, rarely, more serious reactions. These are uncommon but important, and any severe abdominal pain, persistent vomiting, or signs of an allergic reaction warrant urgent medical attention.
These warnings apply to the FDA-approved products; compounded formulations carry the same molecular risks without formulation-specific safety data.
| Warning | Note |
|---|---|
| Thyroid C-cell tumors | Boxed warning; contraindicated with MTC/MEN2 history |
| Pancreatitis | Uncommon; seek care for severe abdominal pain |
| Gallbladder | Risk with rapid weight loss |
Managing side effects
The primary evidence-based strategy is slow dose titration, which is exactly why both drugs are escalated gradually rather than started at full dose. Eating smaller meals, avoiding high-fat foods, and staying hydrated are commonly advised, though the strongest evidence supports the titration schedule itself.
Persistent or worsening symptoms should be reported to the prescribing clinician rather than managed alone, and dose adjustments are a clinical decision. Do not self-adjust dosing to control side effects.
Frequently asked questions
Which has fewer side effects, semaglutide or tirzepatide?
Their profiles are broadly similar, both dominated by GI effects. Some people tolerate one better, but there is no universal rule that either is gentler.
Do side effects go away?
They are usually worst during dose escalation and often ease as the body adjusts. Slow titration is designed to reduce them.
When should I seek medical care?
For severe abdominal pain, persistent vomiting, signs of an allergic reaction, or any severe or worsening symptom, seek urgent care.
Sources
- Clinical trials via NEJM.
- STEP and SURMOUNT trial safety data.
- FDA — human drug compounding and GLP-1 status.